Abivax SA (ABVX.PA) stock: key figures, P/E, revenue and dividend
Health Care · France · ISIN FR0012333284
Abivax SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 10.00 m EUR | 0.00 EUR |
| Gross profit | 10.00 m EUR | -1.00 m EUR |
| Operating income | -172.98 m EUR | -246.06 m EUR |
| EBIT | -185.00 m EUR | -250.00 m EUR |
| Net income | -176.00 m EUR | -336.00 m EUR |
| Diluted EPS – continuing operations | -2.79 EUR | -4.83 EUR |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
More stocks
- CNOOC Energy Technology & Services Ltd (600968.SS)
- Asahi Intecc Co Ltd (7747.T)
- Birkenstock Holding PLC (BIRK)
- EnerSys (ENS)
- Zheshang Securities Co Ltd (601878.SS)
- EFG International AG (EFGN.SW)
- Abivax SA American Depositary Shares (ABVX)
- Wuhan Jingce Electronic Technology Co Ltd (300567.SZ)
- Mineral Res (MALRY)
- RHYTHM PHARMACEUTICALS, INC. (RYTM)
- ExlService Holdings, Inc. (EXLS)
- Ingredion Inc (INGR)
Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.